Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

AN2 Therapeutics, Inc.

ANTX · Nasdaq · CIK 0001880438 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

1 qualifying P purchase group
in the current 180-day scoring window

20 Form 4 transaction lines observed in the same window
11 sales · 8 option, withholding, award, gift or other lines

Last qualifying purchase2026-09-01 · FitzPatrick Margaret M · $11.6K

WHY NO ACTIVE SIGNAL?

Purchase activityPresent
Recent buying1 qualifying line group(s)
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Readnour Robin ShaneDirector
▼▼▼▼
Williams Sarah JoannePrincipal Accounting Officer
▼▼
Aziz KabeerDirector
○○
Marks Gilbert LynnDirector
○○
Martin Patricia A.Director
○○
Trenor Cameron C. IIIChief Medical Officer
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 3 additional owner(s) remain in Form 4 evidence.

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: FitzPatrick Margaret M · $11.6K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-09-01–2026-09-01

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-09-01 · FitzPatrick Margaret M.

Recent Form 4 activity

1Purchases
22Sales
19Other Form 4 lines
33SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING11 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-4.0%
3M
+29.5%
6M
+74.6%
12M
—

Volatility & liquidity

Volatility
132.0%
Beta
—
Avg daily value
—

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
-66.3%
Industry
Biotechnology

Market data

Price data up to: 2026-10-03 · Price source: OpenBB/yfinance · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
2,491,971
Previous report
2,397,307
Avg daily volume
261,160
Days to cover
9.5

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-01FitzPatrick Margaret MPurchase (P)Common Stock2,098USD 5.53USD 11,602SEC filing ↗
2025-06-02Easom EricPurchase (P)Common Stock10,000USD 1.07USD 10,700SEC filing ↗
2025-05-28FitzPatrick Margaret MPurchase (P)Common Stock8,610USD 1.18USD 10,160SEC filing ↗
2024-12-10Readnour Robin ShanePurchase (P)Common Stock5,000USD 1.49USD 7,450SEC filing ↗
2024-12-09Readnour Robin ShanePurchase (P)Common Stock30,772USD 1.43USD 44,004SEC filing ↗
2024-12-06Readnour Robin ShanePurchase (P)Common Stock19,228USD 1.45USD 27,881SEC filing ↗
2024-11-27Zakrzewski Joseph SPurchase (P)Common Stock2,000USD 1.40USD 2,800SEC filing ↗
2024-11-27Readnour Robin ShanePurchase (P)Common Stock25,000USD 1.42USD 35,500SEC filing ↗
2024-11-26Readnour Robin ShanePurchase (P)Common Stock12,500USD 1.39USD 17,375SEC filing ↗
2024-11-20Readnour Robin ShanePurchase (P)Common Stock50,000USD 1.15USD 57,750SEC filing ↗
2024-11-19Readnour Robin ShanePurchase (P)Common Stock150,000USD 1.03USD 155,250SEC filing ↗
2024-11-19Zakrzewski Joseph SPurchase (P)Common Stock5,000USD 1.01USD 5,050SEC filing ↗
2024-11-18Zakrzewski Joseph SPurchase (P)Common Stock20,000USD 1.00USD 20,000SEC filing ↗
2024-11-18Easom EricPurchase (P)Common Stock50,000USD 1.00USD 50,000SEC filing ↗
2024-08-14Leonard Braden MichaelPurchase (P)Common Stock1,500,000USD 1.04USD 1,560,000SEC filing ↗

Form 4 evidence

42 transaction lines in the latest 365-day window; 217 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-12Martin Patricia A.Award / grant (A)Common Stock389USD 0.00USD 0SEC filing ↗
2026-10-12Marks Gilbert LynnAward / grant (A)Common Stock2,283USD 0.00USD 0SEC filing ↗
2026-10-12Aziz KabeerAward / grant (A)Common Stock2,465USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-12Martin Patricia A.Award / grant (A)Common Stock389USD 0.00USD 0SEC filing ↗
2026-10-12Marks Gilbert LynnAward / grant (A)Common Stock2,283USD 0.00USD 0SEC filing ↗
2026-10-12Aziz KabeerAward / grant (A)Common Stock2,465USD 0.00USD 0SEC filing ↗
2026-09-15Trenor Cameron C. IIIAward / grant (A)Common Stock116,667USD 0.00USD 0SEC filing ↗
2026-09-09Readnour Robin ShaneSale (S)Common Stock1,108USD 6.02USD 6,670SEC filing ↗
2026-09-08Readnour Robin ShaneSale (S)Common Stock10,019USD 6.02USD 60,314SEC filing ↗
2026-09-03Readnour Robin ShaneSale (S)Common Stock6,100USD 6.07USD 37,027SEC filing ↗
2026-09-01Williams Sarah JoanneSale (S)Common Stock272USD 5.53USD 1,504SEC filing ↗
2026-09-01FitzPatrick Margaret MPurchase (P)Common Stock2,098USD 5.53USD 11,602SEC filing ↗
2026-08-17Readnour Robin ShaneSale (S)Common Stock35,402USD 6.01USD 212,766SEC filing ↗
2026-08-14Zakrzewski Joseph SGift (G)Common Stock405,880USD 0.00USD 0SEC filing ↗
2026-07-10Martin Patricia A.Award / grant (A)Common Stock766USD 0.00USD 0SEC filing ↗
2026-07-10Marks Gilbert LynnAward / grant (A)Common Stock2,789USD 0.00USD 0SEC filing ↗
2026-07-10Aziz KabeerAward / grant (A)Common Stock2,852USD 0.00USD 0SEC filing ↗
2026-07-08Eizen Joshua MSale (S)Common Stock5,945USD 4.17USD 24,791SEC filing ↗
2026-05-29Williams Sarah JoanneSale (S)Common Stock265USD 4.43USD 1,174SEC filing ↗
2026-04-10Martin Patricia A.Award / grant (A)Common Stock1,192USD 0.00USD 0SEC filing ↗
2026-04-10Marks Gilbert LynnAward / grant (A)Common Stock3,775USD 0.00USD 0SEC filing ↗
2026-04-10Aziz KabeerAward / grant (A)Common Stock3,775USD 0.00USD 0SEC filing ↗
2026-03-03Williams Sarah JoanneSale (S)Common Stock327USD 1.06USD 347SEC filing ↗
2026-02-20Williams Sarah JoanneAward / grant (A)Common Stock48,375USD 0.00USD 0SEC filing ↗
2026-02-20Eizen Joshua MAward / grant (A)Common Stock50,000USD 0.00USD 0SEC filing ↗
2026-02-20Easom EricAward / grant (A)Common Stock112,250USD 0.00USD 0SEC filing ↗
2026-02-20Day LucyAward / grant (A)Common Stock38,000USD 0.00USD 0SEC filing ↗
2026-02-20Chanda SanjayAward / grant (A)Common Stock38,000USD 0.00USD 0SEC filing ↗
2026-01-12Martin Patricia A.Award / grant (A)Common Stock3,650USD 0.00USD 0SEC filing ↗
2026-01-12Marks Gilbert LynnAward / grant (A)Common Stock11,560USD 0.00USD 0SEC filing ↗
2026-01-12Aziz KabeerAward / grant (A)Common Stock11,560USD 0.00USD 0SEC filing ↗
2026-01-06Prior Stephen DavidSale (S)Common Stock2,858USD 1.01USD 2,887SEC filing ↗
2026-01-06Eizen Joshua MSale (S)Common Stock6,931USD 1.01USD 7,000SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerANTX
CIK0001880438
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history217 transaction lines from 2022-03-29 to 2026-10-12
35 P purchase lines · 103 S sale lines · 79 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.